Pregnant women and their fetuses are increasingly likely to be exposed toantipsychotics. However, safety data remain limited. This editorial suggeststhat, in future, well-designed observational pharmaco-epidemiology is ourbest chance of illuminating risk for exposed populations and of informingdecision-making for women and clinicians.